Ahn, M.-J., Chiu, C.-H., Cheng, Y., Han, J.-Y., Goldberg, S. B., Greystoke, A., … Mok, T. S. K. (2019). Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study. In Ann Oncol (Vol. 30 Suppl 2, p. ii48). England. https://doi.org/10.1093/annonc/mdz063.003

Ahn, M. -. J., C. -. H. Chiu, Y. Cheng, J. -. Y. Han, S. B. Goldberg, A. Greystoke, J. Crawford, et al. “Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study.” In Ann Oncol, 30 Suppl 2:ii48, 2019. https://doi.org/10.1093/annonc/mdz063.003.

Ahn M-J, Chiu C-H, Cheng Y, Han J-Y, Goldberg SB, Greystoke A, et al. Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study. In: Ann Oncol. 2019. p. ii48.

Ahn, M. .. J., et al. “Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study.” Ann Oncol, vol. 30 Suppl 2, 2019, p. ii48. Pubmed, doi:10.1093/annonc/mdz063.003.

Ahn M-J, Chiu C-H, Cheng Y, Han J-Y, Goldberg SB, Greystoke A, Crawford J, Zhao Y, Huang X, Johnson M, Vishwanathan K, Mendoza-Naranjo A, Mok TSK. Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study. Ann Oncol. 2019. p. ii48.